Analysis of vaginal late adverse events of radical radiotherapy for patients with cervical cancer

We retrospectively analyzed vaginal late adverse events of 124 cervical cancer patients who underwent radical radiotherapy in 2008-2018. Majority of the patients in the present study were treated with external-beam radiotherapy for pelvis and two-dimensional planning brachytherapy. 3-year actuarial estimate for ≧grade 2 and ≧grade 3 were 21.2% and 4.1%, respectively. In multivariate analysis, total dose of ICRU-RP (odds ratio = 3.3 ; p = 0.046) was the risk factor for vaginal morbidity. ICRU-RP seemed to be useful as an evaluation point for vaginal adverse events. Central shielding during intracavitary irradiation contributed to the reduction of vaginal adverse events by decreasing the dose of ICRU-RP. (author)